DSGN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 31.20%

Insider Buying (Last 12 Months): $99,750.38

Insider Selling (Last 12 Months): $3,487,078.12

Design Therapeutics Insider Trading History Chart

Design Therapeutics Share Price & Price History

^$6.25

▲ +0.26 (4.34%)

As of 12/20/2024 06:16 PM ET

Days: 30 | 90 | 365

⭕ [URGENT] Buy Alert just triggered

From Behind the Markets | Ad

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

Design Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/18/2024	Deepa Prasad	Director	Sell	3,806	$6.27	$23,863.62	20,000
8/9/2024	Arsani William	Director	Sell	814,874	$4.25	$3,463,214.50
3/25/2024	John P Schmid	Director	Buy	17,809	$3.74	$66,605.66	26,965
3/22/2024	John P Schmid	Director	Buy	9,156	$3.62	$33,144.72	9,156
9/29/2023	Rodney W Lappe	Director	Buy	21,000	$2.35	$49,350.00	133,024
8/29/2023	Deepa Prasad	Director	Buy	12,000	$2.31	$27,720.00	23,806
12/20/2022	Sr One Capital Fund I Aggregat	Major Shareholder	Buy	40,000	$8.14	$325,600.00	6,526,476
12/19/2022	Joao Md Siffert	CEO	Buy	1,150	$8.47	$9,740.50	126,319
12/19/2022	Simeon George	Director	Buy	360,000	$8.63	$3,106,800.00	6,486,476
12/16/2022	Simeon George	Director	Buy	500,000	$8.28	$4,140,000.00	6,126,476
12/9/2022	Rodney W Lappe	Director	Buy	15,000	$7.96	$119,400.00	112,024
3/21/2022	Arsani William	Director	Buy	25,000	$18.99	$474,750.00
3/18/2022	Stella Xu	Director	Sell	565,425	$19.07	$10,782,654.75

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

SEC Filings (Institutional Ownership Changes) for Design Therapeutics (NASDAQ:DSGN)

56.64% of Design Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Design Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/20/2024	Virtu Financial LLC	46,356	$0.25M	0.0%	+318.8%	0.082%
11/19/2024	Barclays PLC	96,635	$0.52M	0.0%	+34.2%	0.171%
11/16/2024	Geode Capital Management LLC	758,550	$4.08M	0.0%	+7.1%	1.340%
11/15/2024	Frazier Life Sciences Management L.P.	1,892,547	$10.18M	0.4%	+58.3%	3.342%
11/15/2024	Barclays PLC	96,635	$0.52M	0.0%	+34.2%	0.171%
11/15/2024	Public Employees Retirement System of Ohio	8,272	$45K	0.0%	-63.1%	0.015%
11/15/2024	Jane Street Group LLC	24,003	$0.13M	0.0%	-58.5%	0.042%
11/15/2024	State Street Corp	690,826	$3.72M	0.0%	-0.7%	1.220%
11/15/2024	Point72 Asset Management L.P.	1,600,740	$8.61M	0.0%	+61.6%	2.827%
11/15/2024	Jacobs Levy Equity Management Inc.	280,271	$1.51M	0.0%	-41.2%	0.495%
11/15/2024	Baker BROS. Advisors LP	1,743,725	$9.38M	0.1%	+2.9%	3.080%
11/15/2024	Paloma Partners Management Co	11,902	$64K	0.0%	N/A	0.021%
11/14/2024	PDT Partners LLC	36,099	$0.19M	0.0%	+33.1%	0.064%
11/14/2024	Walleye Capital LLC	70,000	$0.38M	0.0%	+16.3%	0.124%
11/14/2024	MetLife Investment Management LLC	19,334	$0.10M	0.0%	N/A	0.034%
11/13/2024	Caz Investments LP	15,000	$81K	0.0%	-62.5%	0.026%
11/13/2024	FMR LLC	828,665	$4.46M	0.0%	+922.8%	1.464%
11/13/2024	The Manufacturers Life Insurance Company	13,221	$71K	0.0%	N/A	0.023%
11/12/2024	Charles Schwab Investment Management Inc.	257,432	$1.39M	0.0%	+43.0%	0.455%
11/5/2024	GSA Capital Partners LLP	173,744	$0.94M	0.1%	-17.2%	0.307%
10/28/2024	Palumbo Wealth Management LLC	36,774	$0.20M	0.1%	+11.3%	0.065%
10/3/2024	SG Americas Securities LLC	12,289	$66K	0.0%	N/A	0.022%
9/16/2024	Cubist Systematic Strategies LLC	23,497	$79K	0.0%	+75.6%	0.042%
8/19/2024	Point72 Asset Management L.P.	990,801	$3.32M	0.0%	+66.9%	1.754%
8/16/2024	Almitas Capital LLC	1,253,248	$4.20M	1.7%	+22.1%	2.218%
8/16/2024	Frazier Life Sciences Management L.P.	1,195,179	$4M	0.2%	N/A	2.116%
8/14/2024	Squarepoint Ops LLC	89,955	$0.30M	0.0%	+146.9%	0.159%
8/14/2024	Cubist Systematic Strategies LLC	23,497	$79K	0.0%	+75.6%	0.042%
8/14/2024	Marshall Wace LLP	24,280	$81K	0.0%	N/A	0.043%
8/12/2024	Hsbc Holdings PLC	44,470	$0.15M	0.0%	-8.9%	0.079%
8/9/2024	Renaissance Technologies LLC	384,075	$1.29M	0.0%	-15.3%	0.680%
8/9/2024	Dimensional Fund Advisors LP	80,953	$0.27M	0.0%	+119.7%	0.143%
8/8/2024	American Century Companies Inc.	21,333	$71K	0.0%	N/A	0.038%
8/6/2024	Acadian Asset Management LLC	583,160	$1.95M	0.0%	+44.5%	1.032%
7/26/2024	Bank of New York Mellon Corp	118,110	$0.40M	0.0%	+2.5%	0.209%
5/29/2024	Opaleye Management Inc.	113,038	$0.46M	0.1%	N/A	0.200%
5/16/2024	Jacobs Levy Equity Management Inc.	502,020	$2.02M	0.0%	-8.6%	0.889%
5/15/2024	Baker BROS. Advisors LP	1,662,120	$6.70M	0.1%	+10.8%	2.942%
5/15/2024	Public Employees Retirement System of Ohio	23,748	$96K	0.0%	-9.8%	0.042%
5/15/2024	Price T Rowe Associates Inc. MD	11,147	$45K	0.0%	N/A	0.020%
5/10/2024	Acadian Asset Management LLC	403,546	$1.63M	0.0%	+123.3%	0.714%
5/10/2024	Vanguard Group Inc.	1,285,962	$5.18M	0.0%	+29.0%	2.276%
5/9/2024	State Board of Administration of Florida Retirement System	12,630	$51K	0.0%	N/A	0.022%
5/8/2024	Bleakley Financial Group LLC	11,495	$46K	0.0%	N/A	0.020%
5/7/2024	SG Americas Securities LLC	11,316	$46K	0.0%	-40.0%	0.020%
5/3/2024	GSA Capital Partners LLP	216,347	$0.87M	0.1%	+199.3%	0.383%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	14,133	$57K	0.0%	N/A	0.025%
4/29/2024	Principal Financial Group Inc.	12,497	$50K	0.0%	-17.9%	0.022%
4/24/2024	Simplicity Wealth LLC	11,495	$46K	0.0%	N/A	0.020%
4/24/2024	Assenagon Asset Management S.A.	347,794	$1.40M	0.0%	+41.8%	0.616%
4/23/2024	BML Capital Management LLC	879,478	$3.54M	2.3%	-14.6%	1.557%
2/16/2024	Public Employees Retirement System of Ohio	26,338	$70K	0.0%	N/A	0.047%
2/14/2024	Pale Fire Capital SE	10,500	$28K	0.0%	N/A	0.019%
2/13/2024	Tower Research Capital LLC TRC	21,503	$57K	0.0%	+30.2%	0.038%
1/31/2024	Federated Hermes Inc.	11,999	$32K	0.0%	+317.6%	0.021%
1/30/2024	BML Capital Management LLC	1,029,478	$2.73M	2.1%	N/A	1.838%
1/25/2024	Nisa Investment Advisors LLC	11,560	$31K	0.0%	+38,433.3%	0.021%
11/15/2023	RTW Investments LP	2,512,986	$5.93M	0.1%	+60.8%	4.488%
11/14/2023	Corton Capital Inc.	27,134	$64K	0.0%	+56.6%	0.048%
11/14/2023	Prescott Group Capital Management L.L.C.	180,000	$0.43M	0.1%	N/A	0.321%
11/13/2023	Algert Global LLC	35,620	$84K	0.0%	+83.3%	0.064%
11/7/2023	Barclays PLC	71,678	$0.17M	0.0%	+353.1%	0.128%
11/7/2023	Jump Financial LLC	46,700	$0.11M	0.0%	+284.7%	0.083%
11/6/2023	Assenagon Asset Management S.A.	248,047	$0.59M	0.0%	-17.8%	0.443%
11/2/2023	Principal Financial Group Inc.	716,818	$1.69M	0.0%	-1.6%	1.280%
10/26/2023	Strs Ohio	72,800	$0.17M	0.0%	N/A	0.130%
10/13/2023	SG Americas Securities LLC	19,907	$47K	0.0%	N/A	0.036%
8/14/2023	UniSuper Management Pty Ltd	102,919	$0.65M	0.0%	N/A	0.184%
8/11/2023	Trexquant Investment LP	46,524	$0.29M	0.0%	-8.5%	0.083%
8/11/2023	ExodusPoint Capital Management LP	265,384	$1.67M	0.0%	+70.0%	0.474%
8/8/2023	Candriam S.C.A.	185,000	$1.17M	0.0%	N/A	0.331%
8/7/2023	Principal Financial Group Inc.	728,221	$4.59M	0.0%	+1.2%	1.302%
8/2/2023	Bank of Montreal Can	99,240	$0.63M	0.0%	N/A	0.177%
7/25/2023	Assenagon Asset Management S.A.	301,688	$1.90M	0.0%	+79.3%	0.539%
5/16/2023	Avoro Capital Advisors LLC	3,500,000	$20.20M	0.3%	+54.0%	6.256%
5/16/2023	Baker BROS. Advisors LP	626,884	$3.62M	0.0%	-9.4%	1.121%
5/11/2023	ExodusPoint Capital Management LP	156,138	$0.90M	0.0%	+207.8%	0.279%
5/9/2023	Principal Financial Group Inc.	719,937	$4.15M	0.0%	-8.0%	1.287%
5/8/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	19,306	$0.11M	0.0%	+15.7%	0.035%
5/3/2023	Jump Financial LLC	58,800	$0.34M	0.0%	+93.4%	0.105%
4/28/2023	SG Americas Securities LLC	15,040	$87K	0.0%	N/A	0.027%
4/18/2023	Assenagon Asset Management S.A.	168,215	$0.97M	0.0%	N/A	0.301%
2/15/2023	Avoro Capital Advisors LLC	2,272,222	$23.31M	0.3%	+2.3%	4.064%
2/14/2023	RA Capital Management L.P.	2,971,231	$30.49M	0.6%	+7.1%	5.314%
2/14/2023	EcoR1 Capital LLC	884,903	$9.08M	0.3%	-65.7%	1.583%
2/9/2023	Principal Financial Group Inc.	782,709	$8.03M	0.0%	-4.5%	1.400%
2/9/2023	Citigroup Inc.	109,660	$1.13M	0.0%	+220.0%	0.196%
2/8/2023	SR One Capital Management LP	6,526,476	$66.96M	24.4%	+16.0%	11.673%
2/7/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	16,689	$0.16M	0.0%	N/A	0.030%
11/15/2022	Bellevue Group AG	34,881	$0.58M	0.0%	N/A	0.062%
11/14/2022	Tudor Investment Corp Et Al	27,866	$0.47M	0.0%	+116.0%	0.050%
11/14/2022	Cormorant Asset Management LP	5,000,000	$83.60M	5.8%	-9.1%	8.943%
11/14/2022	RA Capital Management L.P.	2,773,231	$46.37M	1.0%	+26.8%	4.960%
11/14/2022	Integral Health Asset Management LLC	125,000	$2.09M	0.4%	N/A	0.224%
11/14/2022	MetLife Investment Management LLC	22,045	$0.37M	0.0%	+30.6%	0.039%
11/14/2022	Ghost Tree Capital LLC	100,000	$1.67M	0.5%	-63.6%	0.179%
11/10/2022	ExodusPoint Capital Management LP	51,841	$0.87M	0.0%	N/A	0.093%
11/8/2022	New York State Common Retirement Fund	24,246	$0.41M	0.0%	+11.1%	0.043%
11/7/2022	TD Asset Management Inc.	16,318	$0.27M	0.0%	-30.9%	0.029%
11/3/2022	Barclays PLC	21,598	$0.36M	0.0%	-89.5%	0.039%

Data available starting January 2016

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Today's Range

Now: $6.25

$5.86

$6.38

50 Day Range

MA: $5.90

$5.15

$7.50

52 Week Range

Now: $6.25

$2.24

$7.77

Volume

578,167 shs

Average Volume

236,970 shs

Market Capitalization

$353.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Who are the company insiders with the largest holdings of Design Therapeutics?: Design Therapeutics' top insider shareholders include:
Rodney W Lappe (Director)
John P Schmid (Director)
Deepa Prasad (Director)
Arsani William (Director)
Learn More about top insider investors at Design Therapeutics.
Who are the major institutional investors of Design Therapeutics?: Design Therapeutics' top institutional shareholders include:
Frazier Life Sciences Management L.P. — 3.34%
Baker BROS. Advisors LP — 3.08%
Point72 Asset Management L.P. — 2.83%
FMR LLC — 1.46%
Geode Capital Management LLC — 1.34%
State Street Corp — 1.22%
Learn More about top institutional investors of Design Therapeutics stock.
Which major investors are selling Design Therapeutics stock?: Within the last quarter, DSGN stock was sold by these institutional investors:
Jacobs Levy Equity Management Inc.
GSA Capital Partners LLP
Jane Street Group LLC
Caz Investments LP
Public Employees Retirement System of Ohio
State Street Corp
In the previous year, company insiders that have sold Design Therapeutics company stock include:
Rodney W Lappe (Director)
John P Schmid (Director)
Learn More investors selling Design Therapeutics stock.
Which major investors are buying Design Therapeutics stock?: In the previous quarter, DSGN stock was bought by institutional investors including:
FMR LLC
Frazier Life Sciences Management L.P.
Point72 Asset Management L.P.
Charles Schwab Investment Management Inc.
Geode Capital Management LLC
Baker BROS. Advisors LP
Virtu Financial LLC
Barclays PLC
Within the previous year, these company insiders have bought Design Therapeutics stock:
Rodney W Lappe (Director)
John P Schmid (Director)
Deepa Prasad (Director)
Learn More investors buying Design Therapeutics stock.